CPRX Catalyst Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CPRX

Price (delayed)

$15.13

Market cap

$1.78B

P/E Ratio

22.58

Dividend/share

N/A

EPS

$0.67

Enterprise value

$1.65B

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), anti-MuSK ...

Highlights
Catalyst Pharmaceuticals's gross profit has surged by 93% YoY and by 15% QoQ
The revenue has soared by 86% YoY and by 14% QoQ
The EPS has declined by 16% year-on-year but it has increased by 14% since the previous quarter
Catalyst Pharmaceuticals's net income has increased by 15% QoQ but it has decreased by 14% YoY
Catalyst Pharmaceuticals's quick ratio has shrunk by 53% YoY and by 14% QoQ
The stock's P/E is 37% more than its 5-year quarterly average of 16.5 and 21% more than its last 4 quarters average of 18.6
Sector: Healthcare
Industry: Biotechnology
Website: http://www.catalystpharma.com
Peers: SRPT JNJ BMRN ABT

Key stats

What are the main financial stats of CPRX
Market
Shares outstanding
117.86M
Market cap
$1.78B
Enterprise value
$1.65B
Valuations
Price to earnings (P/E)
22.58
Price to book (P/B)
4.16
Price to sales (P/S)
4.04
EV/EBIT
17.45
EV/EBITDA
12.92
EV/Sales
4.14
Earnings
Revenue
$398.2M
EBIT
$94.51M
EBITDA
$127.65M
Free cash flow
$143.37M
Per share
EPS
$0.67
Free cash flow per share
$1.35
Book value per share
$3.64
Revenue per share
$3.75
TBVPS
$2.6
Balance sheet
Total assets
$470.11M
Total liabilities
$82.23M
Debt
$3.19M
Equity
$387.88M
Working capital
$143.27M
Liquidity
Debt to equity
0.01
Current ratio
2.88
Quick ratio
2.51
Net debt/EBITDA
-1.05
Margins
EBITDA margin
32.1%
Gross margin
86.9%
Net margin
17.9%
Operating margin
21.8%
Efficiency
Return on assets
16.5%
Return on equity
19.8%
Return on invested capital
190.7%
Return on capital employed
24%
Return on sales
23.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CPRX stock price

How has the Catalyst Pharmaceuticals stock price performed over time
Intraday
-1.37%
1 week
-0.59%
1 month
-7.69%
1 year
-12.69%
YTD
-9.99%
QTD
-5.08%

Financial performance

How have Catalyst Pharmaceuticals's revenue and profit performed over time
Revenue
$398.2M
Gross profit
$346.24M
Operating income
$86.81M
Net income
$71.41M
Gross margin
86.9%
Net margin
17.9%
Catalyst Pharmaceuticals's gross profit has surged by 93% YoY and by 15% QoQ
The revenue has soared by 86% YoY and by 14% QoQ
The operating margin has shrunk by 54% YoY
Catalyst Pharmaceuticals's net margin has shrunk by 54% YoY

Growth

What is Catalyst Pharmaceuticals's growth rate over time

Valuation

What is Catalyst Pharmaceuticals stock price valuation
CPRX P/E details
P/E
22.58
P/B
4.16
P/S
4.04
EV/EBIT
17.45
EV/EBITDA
12.92
EV/Sales
4.14
The stock's P/E is 37% more than its 5-year quarterly average of 16.5 and 21% more than its last 4 quarters average of 18.6
The EPS has declined by 16% year-on-year but it has increased by 14% since the previous quarter
Catalyst Pharmaceuticals's equity has increased by 29% YoY and by 11% QoQ
The stock's price to book (P/B) is 3.3% less than its last 4 quarters average of 4.3
The revenue has soared by 86% YoY and by 14% QoQ
The price to sales (P/S) is 21% lower than the 5-year quarterly average of 5.1 and 18% lower than the last 4 quarters average of 4.9

Efficiency

How efficient is Catalyst Pharmaceuticals business performance
The ROIC has dropped by 63% year-on-year and by 27% since the previous quarter
The ROS has dropped by 52% year-on-year but it has increased by 2.2% since the previous quarter
CPRX's return on assets is down by 39% year-on-year but it is up by 9% since the previous quarter
The ROE has decreased by 39% YoY but it has increased by 8% from the previous quarter

Dividends

What is CPRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CPRX.

Financial health

How did Catalyst Pharmaceuticals financials performed over time
Catalyst Pharmaceuticals's quick ratio has shrunk by 53% YoY and by 14% QoQ
CPRX's current ratio is down by 48% year-on-year and by 13% since the previous quarter
Catalyst Pharmaceuticals's debt is 99% lower than its equity
Catalyst Pharmaceuticals's equity has increased by 29% YoY and by 11% QoQ
Catalyst Pharmaceuticals's debt has decreased by 10% YoY and by 2.9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.